Fosamax Lawyers at Bernstein Liebhard LLP Comment on New Study Concerning Bisphosphonates and Non-Healing Femur Fractures

Share Article

The Firm’s Fosamax Lawyers are currently investigating Fosamax lawsuits on behalf of individuals who suffered Fosamax femur fractures, allegedly due to long-term Fosamax use.

Bernstein Liebhard LLP | Consumer Injury Lawyers
This study once again highlights the dangers associated with long-term use of bisphosphonates like Fosamax, as well as the seriousness of Fosamax femur fractures.

As Fosamax femur fracture lawsuits continue to move forward in state and federal courts, the Fosamax lawyers at Bernstein Liebhard LLP report that a new study published in the Journal of Bone and Joint Surgery has found an association between bisphosphonates, such as Fosamax, and non-healing femur fractures within the U.S. Food & Drug Administration’s (FDA) Adverse Event Reporting System database. The study, which was based on an analysis of 15-year data from the FDA database on bisphosphonate-associated non-healing femoral fractures, found that 26% of the atypical femoral fractures reported to the FDA exhibited delayed healing or non-healing.*

“This study once again highlights the dangers associated with long-term use of bisphosphonates like Fosamax, as well as the seriousness of Fosamax femur fractures,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices, including dozens of women in Fosamax lawsuits. The Firm’s Fosamax lawyers are currently offering free legal evaluations to alleged victims of Fosamax femur fractures.

Fosamax Femur Fractures
Fosamax has been used by millions of post-menopausal women to prevent fractures from osteoporosis. In October 2010, the U.S. Food & Drug Administration (FDA) added new information to the Fosamax label after studies indicated that people taking bisphosphonates for osteoporosis are at risk of suffering atypical femur fractures. At the time, the FDA was not able to identify a safety signal involving bisphosphonates and atypical femoral fractures reported to its database.* According to the authors of the study appearing in the Journal of Bone and Joint Surgery, their research is the first to identify a safety signal between bisphosphonates and these non-healing femoral fractures .

Since the FDA issued its caution regarding alleged Fosamax femur fractures in October 2010, hundreds of women have filed Fosamax lawsuits in state and federal courts. Court records indicate that 2,566 Fosamax lawsuits have been filed in a consolidated litigation underway in New Jersey Superior Court, Atlantic County, by patients who suffered femur fractures and other side effects, allegedly due to long-term use of Fosamax. Jury selection in the first trial of a Fosamax lawsuit involving femur fracture allegations was scheduled to begin on March 11th. The Fosamax lawyers at Bernstein Liebhard LLP are actively filing claims in this litigation. (In re: Fosamax Litigation, No. 282, N.J. Super. Ct)

In addition to the New Jersey state litigation, federally-filed Fosamax lawsuits involving femur facture claims have been consolidated in a multidistrict litigation in U.S. District Court, District of New Jersey. Court documents indicate that the first of more than 800 Fosamax lawsuits pending in the federal litigation will also go to trial this year. (In re: Fosamax (Alendronate Sodium) Products Liability Litigation (No. II) - MDL No. 2243)

Victims of femur fractures that might be associated with long-term use of Fosamax may be entitled to compensation for medical bills, lost wages, pain and suffering, and other damages. A wealth of information regarding Fosamax lawsuits is available by visiting Bernstein Liebhard LLP’s website, To learn more, please contact the Fosamax lawyers at Bernstein Liebhard LLP at (877) 779-1414.


About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(877) 779-1414

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Follow us on
Visit website